SegCov: Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04563156
Collaborator
(none)
100
1
18.3
5.5

Study Details

Study Description

Brief Summary

Infection with covid-19 is associated with respiratory failure, which when related to other etiologies can lead to reduced quality of life, physical, cognitive and mental dysfunction. There is no knowledge of the possible consequences of severe covid-19 infection.

Our objective is to describe these repercussions, identifying risk factors and assessing the impact of physical training.

At least 100 patients over 18 years of age who survive severe Covid-19 infection will be evaluated. Assessments after 1, 4, 6 and 12 months after hospital discharge. Quality of life, dyspnea, activity of daily living, muscle strength, mental and cognitive dysfunction will be evaluated, as well as pulmonary function test, cardiopulmonary stress test and chest tomography. Return to work, thromboembolic events and mortality up to 12 months will also be monitored.

Hospitalization data will be used to identify factors related to quality of life, fatigue and respiratory dysfunction. Predefined risk factors will be evaluated: age, sex, smoking, previous comorbidities index, previous clinical frailty, serum C-reactive protein and leukocyte / lymphocyte ratio in the first 24 hours of hospitalization, time between onset of symptoms and hospitalization, ICU and mechanical ventilation, time on mechanical ventilation, compliance corrected by the ideal weight at the start of mechanical ventilation, driving pressure, tidal volume corrected by the ideal weight and PEEP (positive end expiratory pressure) after 24 hours of intubation in controlled ventilation, tidal volume corrected by the ideal weight after 24 hours of spontaneous ventilation, inspiratory muscle training and pulmonary rehabilitation after hospital discharge.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Lung Function Test

Detailed Description

Prospective longitudinal study in which survivors of severe infection with the covid-19 virus (need for hospitalization with supplementation of more than 3l / min of oxygen or mechanical ventilation) will be evaluated after 1 month, 4 months, 6 months and 1 year after hospital discharge through distance or face-to-face assessment.

Patients will be included according to a convenience sample until 12/31/2020 with follow-up until 12/31/2021. The EQ-5D questionnaire will be collected to assess quality of life. For other secondary outcomes, the clinical frailty scale, daily life independence scale, MoCA cognition questionnaire, hospital anxiety and depression questionnaire (HADS), muscle strength measure by the MRC scale, dyspnea measure by the mMRC and BDI scale will be used -TDI, 1-minute sit-and-stand test, maximum inspiratory and expiratory pressure measurement. Return to work, occurrence of thromboembolic events, occurrence of falls, need for re-hospitalization and mortality up to 12 months after admission will also be evaluated.

After 6 months of discharge, lung volume measurement will be performed by pulmonary function test, aerobic capacity by cardiopulmonary exercise test and evaluation of anatomical pulmonary sequelae by chest tomography. Patients residing close to the hospital will be offered a physical training program carried out by the physiotherapy team with assessment of functional response indicators.

The data obtained in the follow-up will be crossed with data obtained by the Epicov study in order to identify risk factors related to dysfunctions.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Follow-up and Rehabilitation of Survivors of Severe Covid-19 Infection
Actual Study Start Date :
Jun 23, 2020
Anticipated Primary Completion Date :
Jun 30, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Severe Covid-19 Survivors

Severe Covid-19 survivors previously admitted in the hospital

Diagnostic Test: Lung Function Test
Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
Other Names:
  • Computerized tomography scan
  • Cardiopulmonary Exercise Testing
  • Outcome Measures

    Primary Outcome Measures

    1. Quality of life assessment of a survivor of severe COVID-19 infection 6 months after hospital discharge; [6 months after discharge]

      EQ-5D is a standardized tool for the assessment of quality of life in 5 different dimensions (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression). Possible scores range from 1 (No problem) to 3 (Extreme problems) and each dimension are evaluated individually. Assessment at 6 months after discharge

    Secondary Outcome Measures

    1. Quality of life questionnaire EQ-5D [30, 120 days and 12 months after hospital discharge]

    2. Evaluation of dyspnea by the Modified Medical Research Council Scale (mMRC) [30, 120 days, 6 months and 12 months after hospital discharge]

    3. The Hospital Anxiety and Depression Scale [6 months and 12 months after hospital discharge]

    4. Baseline and Transition Dyspnea Indexes (BDI-TDI) [30 days, 120 days, 6 and 12 months after hospital discharge;]

    5. Clinical frailty scale measured after discharge from the ICU, [30, 120 days, 6 and 12 months after hospital discharge]

    6. Lawton-Brody Instrumental Activities of Daily Living (iADL) scale [30, 120 days, 6 months and 12 months after hospital discharge]

    7. Muscle strength according to the Medical Research Council (MRC) scale [30, 120 days, 6 and 12 months after hospital discharge;]

    8. Maximum inspiratory pressure, diaphragmatic mobility and diaphragm thickness [30, 120 days, 6 and 12 months after hospital discharge]

    9. Sit-to-stand test in 1 minute [30 days, 120 days, 6 and 12 months after hospital]

    10. Cognitive dysfunction measured using the Montreal Cognitive Assessment (MoCA) test [6 months and 12 months after hospital discharge]

    11. Pulmonary function test with Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements [30, 120 days and 6 and 12 months after hospital discharge]

    12. Hemoglobin, hematocrit, creatinine and Fasting plasma glucose (FPG) [6 and 12 months after hospital discharge;]

    13. Quantitative computerized tomography scan [6 months after hospital discharge]

    14. Maximum VO2 during Cardiopulmonary exercise testing [6 and 12 months after hospital discharge]

    15. Return to work [6 months and 12 months after hospital discharge]

    16. Occurrence of thromboembolic events after [6 and 12 months after hospital discharge]

    17. Occurrence of falls [6 and 12 months after hospital discharge]

    18. Need for readmission [6 and 12 months after hospital discharge]

    19. Mortality [6 and 12 months after hospital discharge]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients over 18 years of age

    • Respiratory infection confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) for SARS CoV-2 swab

    • Need for admission to the ICU or ward with need for oxygen greater than 3L / min or mechanical ventilation and has been discharged from hospital.

    Exclusion Criteria:
    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP São Paulo Brazil 05403-000

    Sponsors and Collaborators

    • University of Sao Paulo General Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Sao Paulo General Hospital
    ClinicalTrials.gov Identifier:
    NCT04563156
    Other Study ID Numbers:
    • 4047553
    First Posted:
    Sep 24, 2020
    Last Update Posted:
    Sep 24, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Sao Paulo General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 24, 2020